H5N1 influenza vaccine

BIOLOGICAL3 trials

Sponsors

Novartis Vaccines, BiondVax Pharmaceuticals ltd.

Conditions

Avian InfluenzaHealthyInfluenzaProphylaxis of Avian Influenza

Phase 2

Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years

CompletedNCT00537524

Novartis VaccinesProphylaxis of Avian Influenza

Start: 2007-09-30End: 2008-05-31Updated: 2012-02-16

Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine

CompletedNCT00561184

Novartis VaccinesAvian Influenza

Start: 2007-10-31End: 2008-06-30Updated: 2016-12-01

Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults

CompletedNCT02691130

BiondVax Pharmaceuticals ltd.Healthy, Influenza

Start: 2015-11-30End: 2017-01-31Updated: 2018-02-09